Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells

被引:118
作者
Zhang, YJ
Lou, B
Lal, RB
Gettie, A
Marx, PA
Moore, JP
机构
[1] Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA
[2] Ctr Dis Control & Prevent, DASTLR, Natl Ctr Infect Dis, Atlanta, GA 30333 USA
[3] Tulane Univ, Med Ctr, Covington, LA 70433 USA
关键词
D O I
10.1128/JVI.74.15.6893-6910.2000
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We have used coreceptor-targeted inhibitors to investigate which coreceptors are used by human immunodeficiency virus type I (HIV-1), simian immunodeficiency viruses (SIV), and human immunodeficiency virus type 2 (HIV-2) to enter peripheral blood mononuclear cells (PBMC). The inhibitors are TAK-779, which is specific for CCR5 and CCR2, aminooxypentane-RANTES, which blocks entry via CCR5 and CCR3, and AMD3100, which targets CXCR4. We found that for ail the HIV-1 isolates and all hut one of the HIV-2 isolates tested, the only relevant coreceptors were CCR5 and CXCR4. However, one HIV-2 isolate replicated in human PBMC even in the presence of TAK-779 and AMD3100, suggesting that it might use an undefined, alternative coreceptor that is expressed in the cells of some individuals. SIV(mac)239 and SIV(mac)251 (from macaques) were also able to use an alternative coreceptor to enter PBMC from some, but not all, human and macaque donors. The replication in human PBMC of SIVrcm (from a red-capped mangabey), a virus which uses CCR2 but not CCR5 for entry, was blocked by TAK-779, suggesting that CCR2 is indeed the paramount coreceptor for this virus in primary cells.
引用
收藏
页码:6893 / 6910
页数:18
相关论文
共 118 条
[1]   HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS [J].
Abebe, A ;
Demissie, D ;
Goudsmit, J ;
Brouwer, M ;
Kuiken, CL ;
Pollakis, G ;
Schuitemaker, H ;
Fontanet, AL ;
de Wit, TFR .
AIDS, 1999, 13 (11) :1305-1311
[2]   CC CKRS: A RANTES, MIP-1 alpha, MIP-1 beta receptor as a fusion cofactor for macrophage-tropic HIV-1 [J].
Alkhatib, G ;
Combadiere, C ;
Broder, CC ;
Feng, Y ;
Kennedy, PE ;
Murphy, PM ;
Berger, EA .
SCIENCE, 1996, 272 (5270) :1955-1958
[3]   A new SIV co-receptor, STRL33 [J].
Alkhatib, G ;
Liao, F ;
Berger, EA ;
Farber, JM ;
Peden, KWC .
NATURE, 1997, 388 (6639) :238-238
[4]   A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity [J].
Baba, M ;
Nishimura, O ;
Kanzaki, N ;
Okamoto, M ;
Sawada, H ;
Iizawa, Y ;
Shiraishi, M ;
Aramaki, Y ;
Okonogi, K ;
Ogawa, Y ;
Meguro, K ;
Fujino, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (10) :5698-5703
[5]   Patterns of CCR5, CXCR4, and CCR3 usage by envelope glycoproteins from human immunodeficiency virus type 1 primary isolates [J].
Bazan, HA ;
Alkhatib, G ;
Broder, CC ;
Berger, EA .
JOURNAL OF VIROLOGY, 1998, 72 (05) :4485-4491
[6]   Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease [J].
Berger, EA ;
Murphy, PM ;
Farber, JM .
ANNUAL REVIEW OF IMMUNOLOGY, 1999, 17 :657-700
[7]   A new classification for HIV-1 [J].
Berger, EA ;
Doms, RW ;
Fenyö, EM ;
Korber, BTM ;
Littman, DR ;
Moore, JP ;
Sattentau, QJ ;
Schuitemaker, H ;
Sodroski, J ;
Weiss, RA .
NATURE, 1998, 391 (6664) :240-240
[8]  
Berger EA, 1997, AIDS, V11, pS3
[9]  
Bieniasz P. D., 1998, FRONT BIOSCI, V3, P44
[10]   Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients [J].
Björndal, Å ;
Sönnerborg, A ;
Tscherning, C ;
Albert, J ;
Fenyö, EM .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1999, 15 (07) :647-653